StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen PROCYSBI (cysteamine bitartrate by Quarter

PROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M) ($M)

QuarterlyAnnual

Amgen PROCYSBI (cysteamine bitartrate: $71M in Q2 2026, up 29.1% from a year earlier. That is the highest of the 10 quarters on record here.

Latest, Q2 2026
71
Period ended Jun 30, 2026
Change on a year earlier
+29.1%
55 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
9
Documents cited below

Where the Q2 2026 figure comes from

“|| PROCYSBI — U.S. | 71 | 55 | 29 | % | 118 | 112 | 5 | %”

Source: Form 10-Q (amgn-20260630.htm, filed 2026-08-05) ↗

Reported in Form 10-Q / 10-K Other Product Sales by Geographic Region Footnote.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPROCYSBI (cysteamine bitartrate — Nephropathic Cystinosis) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202671+29.1%Form 10-Q (amgn-20260630.htm, filed 2026-08-05) ↗
Q1 2026Mar 31, 202647-17.5%Form 10-Q (amgn-20260331.htm, filed 2026-05-01) ↗
Q4 2025Dec 31, 202559-3.3%Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Q3 2025Sep 30, 202562+8.8%Form 10-Q (amgn-20250930.htm, filed 2025-11-05) ↗
Q2 2025Jun 30, 202555+1.9%Form 10-Q (amgn-20250630.htm, filed 2025-08-06) ↗
Q1 2025Mar 31, 202557+16.3%Form 10-Q (amgn-20250331.htm, filed 2025-05-02) ↗
Q4 2024Dec 31, 202461–Form 10-K (amgn-20251231.htm, filed 2026-02-13) ↗
Q3 2024Sep 30, 202457–Form 10-Q (amgn-20240930.htm, filed 2024-10-31) ↗
Q2 2024Jun 30, 202454–Form 10-Q (amgn-20240630.htm, filed 2024-08-07) ↗
Q1 2024Mar 31, 202449–Form 10-Q (amgn-20240331.htm, filed 2024-05-03) ↗

Breakdown

What makes up PROCYSBI (cysteamine bitartrate

Cite this data

StockData. (2026). Amgen PROCYSBI (cysteamine bitartrate ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-procysbi-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.